Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
NuVasive Inc. shares are up on a 1st-quarter swing to black ink and the launch of its 1st major new platform in a decade.
San Diego-based NuVasive yesterday announced its Q1 numbers, citing a pair of legal developments that interim CEO Greg Lucier said remove “a significant legal overhang,” and revealed its Integrated Global Alignment system. The news sent NUVA shares up 2.0% to $46.56 apiece today in mid-morning trading. Read more
Evolent Health today registered for a $100 million initial public offering for its value-based healthcare software platform as it looks to capitalize on its estimated $10 billion market.
Arlington, Va.-based Evolent, founded in 2011, said it plans to list on the New York Stock Exchange under the “EVH” symbol. Read more
Medtronic said the FDA cleared its Euphora semicompliant balloon dilation catheter, and the company wasted no time in getting the pre-stenting device on the U.S. market.
Dr. James DeVries of the Dartmouth-Hitchcock Medical Center in Lebanon, N.H., performed the 1st commercial case to use the Euphora device, Medtronic said. It’s designed to re-open a clogged coronary artery to prepare the lesion for a stent, the company said. Read more